Masui Takuya, Hashimoto Ryota, Kusumi Ichiro, Suzuki Katsuji, Tanaka Teruaki, Nakagawa Shin, Suzuki Tatsuyo, Iwata Nakao, Ozaki Norio, Kato Tadafumi, Kunugi Hiroshi, Koyama Tsukasa
Psychiatr Genet. 2006 Apr;16(2):49-50. doi: 10.1097/01.ypg.0000180680.72922.57.
Lithium is a first-line agent for the treatment of bipolar disorder. A significant association between the Val66Met polymorphism of the brain-derived neurotrophic factor gene and bipolar disorder has been reported. We investigated whether this polymorphism is associated with the response to lithium treatment in Japanese patients with bipolar disorder. Patients had been treated with lithium carbonate for more than 1 year, and the response was retrospectively evaluated. No significant differences were found in the genotype distribution or allele frequency between responders and non-responders. Our results suggested that the brain-derived neurotrophic factor Val66Met polymorphism might not greatly contribute to the efficacy of lithium in bipolar disorder.
锂是治疗双相情感障碍的一线药物。据报道，脑源性神经营养因子基因的Val66Met多态性与双相情感障碍之间存在显著关联。我们调查了这种多态性是否与日本双相情感障碍患者对锂治疗的反应有关。患者接受碳酸锂治疗超过1年，并对反应进行了回顾性评估。在反应者和无反应者之间，基因型分布或等位基因频率没有发现显著差异。我们的结果表明，脑源性神经营养因子Val66Met多态性可能对锂治疗双相情感障碍的疗效贡献不大。
